Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

OTCQB:NWBO - Post by User

Northwest Biotherapeutics Inc

Bullboard Posts

Comment by pericles1on Apr 13, 2014 6:08am

74 Views

Post# 22444790

RE:New Financing!

Another thing I did not like about the announcement of the financing is saying no warrants were involved. This is technically correct in that it's only a right to buy and for a set time and cannot be transferred, but Linda is stretching the truth in my opinion. In most respects it acts much in the same way a warrant would. To be honest she should just have not said anything about it not being a warrant. Dam, investing is not easy!

Bullboard Posts

Understanding tax loss season and the “Santa Claus rally”